Efficacy of topical mineralocorticoids in a rabbit model of ocular inflammation

Abstract

Objectives: The aim of this study was to determine the efficacy of mineralocorticoids in the treatment of ocular inflammation, whose potential use has not been assessed.

Methods: Thirty-five New Zealand albino rabbits were used in the study. Rabbits were divided into five groups. Only one eye was used for experimental purposes and the other eye was used as control. 11-deoxycortisol, deoxycorticosterone acetate, fludrocortisone acetate, aldosterone and 11-deoxycorticosterone were studied in a rabbit model of ocular inflammation. All animals in a group received the same corticosteroid. Paired t-tests and analysis of variance between subjects (ANOVA) were used to evaluate efficacy.

Results: The eyes treated with 11-deoxycortisol, deoxycorticosterone acetate, and fludrocortisone acetate had statistically significant lower fluorescence compared to control eyes. 11-deoxycortisol and deoxycorticosterone acetate provided a greater reduction in fluorescence compared to other corticosteroids.

Conclusions: Topical use of corticosteroids, especially those with mineralocorticoid activity can decrease ocular inflammation in a rabbit model. Clinical application of topical mineralocorticoids in human ocular inflammation needs to be performed.

Keywords

• Topical mineralocorticoids
• ocular inflammation
• uveitis

References

1. 1. Fraunfelder FW, Rosenbaum JT. Drug induced uveitis. Incidence, prevention and treatment. Drug Saf 1997;17:197-207.
2. 2. Dunn JP, Nozik RA. Uveitis: Role of physician in treating systemic causes. Geriatrics 1994;49:27-32.
3. 3. McCluskey P, Powell RJ. The eye in systemic inflammatory diseases. Lancet 2004;364:2125-33.
4. 4. Martin TM, Smith JR, Rosenbaum JT. Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies. Curr Opin Rheumatol 2002;14:337-41.
5. 5. Afshari NA, Afshari MA, Foster CS. Inflammatory conditions of the eye associated with rheumatic disease. Curr Rheumatol Rep 2001;3:453-8.
6. 6. Gaudio PA. A review of evidence guiding the use of corticosteroids in the treatment of intraocular inflammation. Ocul Immunol Inflamm 2004;12:169-92.
7. 7. Herman DC. Endogenous uveitis: Current concepts of treatment. Mayo Clin Proc 1990;65:671-83.
8. 8. McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf 2002;25:33-55.

9. 9. Weijtens O, Schoemaker RC, Romijn FP, Cohen AF, Lentjes EG, van Meurs JC. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmology 2002;109:1887-97.
10. 10. Weijtens O, Feron EJ, Schoemaker RC, Cohen AF, Lentjes EG, Romijn FP, van Meurs JC. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am J Ophthalmol 1999;128:192-7.
11. 11. Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye 2006;20:407-16.
12. 12. Mirshahi M, Nicolas C, Mirshahi A, Hecquet C, d'Hermies F, Faure JP, Agarwal MK. The mineralocorticoid hormone receptor and action in the eye. Biochem Biophys Res Commun 1996;219:150-6.
13. 13. Mirshahi M, Agerwal MK. Receptor-mediated adrenocorticoid hormone signaling in ocular tissue. Biochem Pharmacol 2003;65:1207-14.
14. 14. Golestaneh N, Picaud S, Mirshahi M. The mineralocorticoid receptor in rodent retina: Ontogeny and molecular identity. Mol Vis 2002;8:221-5.
15. 15. Suzuki T, Sasano H, Kaneko C, Ogawa S, Darnel AD, Krozowski ZS. Immunohistochemical distribution of libeta-hydroxysteroid dehydrogenase in human eye. Mol Cell Endocrinol 2001;173:121-5.
16. 16. Mirshahi M, Mirshahi S, Golestaneh N, Nicolas C, Mishal Z, Lounes KC, et al. Mineralocorticoid hormone signaling regulates the ‘epithelial sodium channel’ in fibroblasts from human cornea. Ophthalmic Res 2001;33:7-19.
17. 17. Waterbury LD, Flach AJ. Efficacy of low concentrations of ketorlac tromethamine in animal models of ocular inflammation. J Ocular Pharm Ther 2004;20:345-52.
18. 18. Dubois EF. Clinical potencies of glucocorticoids: what do we really measure? Curr Respir Med Rev 2005;1:103-8.
19. 19. Joffe HV, Adler GK. Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev 2005;10:31-7.
20. 20. Kuster GM, Kotlyar E, Rude MK, Siwik DA, Liao R, Colucci WS, et al. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation 2005;111:420-7.
21. 21. Rooks WH, Malone PJ, Shott LD, Schuler ME, Sevelius H, Strosberg AM, et al. The analgesic and anti-inflammatory profile of ketorlac and its tromethamine salt. Drugs Exp Clin Res 1985;11:479-92.
22. 22. Ohia OE, Mancino M, Kulkarni PS. Effects of steroids and immunosuppressive drugs on endotoxin-uveitis in rabbits. J Ocular Pharm 1992;8:295-307.
23. 23. Stokes J, Noble J, Brett L, Phillips C, Seckl JR, Colm OB, et al. Distribution ofglucocorticoid and mineralocorticoid receptors and 11 beta-hydroxysteroiddehydrogenases in human and rat ocular tissues. Invest Ophthalmol Vis Sci 2000;41:1629-38.
24. 24. Gilbert KC, Brown NJ. Aldosterone and inflammation. Curr Opin Endocrinol Diabetes Obes 2010;17:199-204.
25. 25. Zhao M, Célérier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest 2012;122:2672-9.
26. 26. Bousquet E, Zhao M, Ly A, Leroux les Jardins G, Goldenberg B, Naud MC, et al. The Aldosterone-mineralocorticoid receptor pathway exerts anti-inflammatory effects in endotoxin-induced uveitis. PLoS One 2012;7:e49036.
27. 27. Dahmana N, Gabriel D, Gurny R, Kalia YN. Development and validation of a fast and sensitive UHPLC-ESI-MS method for the simultaneous quantification of spironolactone and its metabolites in ocular tissues. Biomed Chromatogr 2018;32:e4287.
28. 28. Barrera-Chimal J, Jaisser F. Vascular mineralocorticoid receptor activation and disease. Exp Eye Res 2019;188:107796.